NAD recommends Removyl to discontinue certain advertising claims
NEW YORK The National Advertising Division of the Council of Better Business Bureaus on Tuesday recommended that Removyl Corp. discontinue weight-loss claims in advertising for the Removyl Advanced Formula dietary supplement products, including: “Recent studies have shown that the combination of 13 known essential oils prevents fat from building in the body by stimulating the body to break it down and eliminate it on a daily basis;” “It is possible to lose up to 2 lbs. per day in the first three weeks, without any effort;” and “You are going to notice that your weight will have dropped by almost 1 lb. in as little as 8 hours.”
In this case, the NAD noted, the advertiser relied solely on studies on green tea extracts, not on the advertised product Removyl (the essential oils), to support its advertising claims. However, the NAD determined that none of the cited green tea studies supported the specific weight-loss claims being made.
Further, the NAD determined that there was insufficient evidence in the record to support rapid weight-loss claims. While there was limited evidence that certain ingredients in Removyl are recognized as possessing diuretic and laxative properties, there was no evidence that the amounts of these ingredients contained in Removyl would have such effects, and none of the evidence rose to the level that would support specific fast weight-loss claims. The NAD recommended that claims suggesting rapid weight loss be discontinued.
In response to the NAD’s opening letter, Removyl informed the NAD that it has suspended all advertising purchases for Removyl Advanced Formula, and that no further advertising would be booked in the future until the the NAD’s review was complete.
The company, in its advertiser’s statement, added that it has not offered the product for sale since April, although it has shipped remaining orders.
The review is a part of the NAD’s ongoing monitoring program in conjunction with the NAD’s initiative with the Council for Responsible Nutrition.
WHO director-general: H1N1 outcome in Southern Hemisphere positive
CANCUN, Mexico Delivering the keynote speech at a high-level meeting on influenza H1N1 on Thursday, Margaret Chan, director-general of the World Health Organization, suggested that early reports out of the Southern Hemisphere around the severity of the H1N1 pandemic are positive.
“We are still seeing a largely reassuring clinical picture,” she said. “The overwhelming majority of patients experience mild symptoms and make a full recovery within a week, often in the absence of any form of medical treatment. Research published last week confirms that this pattern, in which most patients experience mild influenza-like illness, has also been seen in Mexico.”
Most cases of severe and fatal infection continue to occur in people with underlying medical conditions. Pregnant women are also at increased risk of complications, she said. “But there are some exceptions that must be the focus of particular concern,” she added. “For reasons that are poorly understood, some deaths are occurring in perfectly healthy young people. Moreover, some patients experience a very rapid clinical deterioration, leading to severe, life-threatening viral pneumonia that requires mechanical ventilation.”
Acid-reducing medicines may lead to dependency
NEW YORK Treatment with proton-pump inhibitors could have the opposite of the intended effect in healthy people, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association Institute.
Researchers studied the effects of PPIs for eight weeks, finding that instead of reducing such acid-related symptoms as heartburn, acid regurgitation and dyspepsia post-treatment, the symptoms returned once the therapy ended.
“This study indicates unrecognized aspects of PPI withdrawal and is a very strong indication of a clinically significant acid rebound phenomenon that needs to be investigated in proper patient populations,” said Christina Reimer, MD, of Copenhagen University and lead author of the study.
According to earlier studies, 33% of patients who initiate PPI treatment continue to refill their prescriptions without an obvious indication for maintenance therapy. Rebound acid hypersecretion, defined as an increase in gastric acid secretion above pre-treatment levels following antisecretory therapy, is observed within two weeks after withdrawal of treatment and could theoretically lead to such acid-related symptoms as heartburn, acid regurgitation or dyspepsia that might result in resumption of therapy.
Data showed 44% of those randomized to PPIs reported at least one relevant acid-related symptom compared to 15% in the placebo group.
“We find it highly likely that the symptoms observed in this trial are caused by rebound acid hypersecretion and that this phenomenon is equally relevant in patients treated long term with PPIs. If rebound acid hypersecretion induces acid-related symptoms, this might lead to PPI dependency. Our results justify the speculation that PPI dependency could be one of the explanations for the rapidly and continuously increasing use of PPIs,” said Reimer.